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Escherichia coli Nissle 1917 (EcN) is a probiotic strain with proven efficacy in inducing
and maintaining remission of ulcerative colitis. However, the microbial factors that
mediate these beneficial effects are not fully known. Gram-negative bacteria release
outer membrane vesicles (OMVs) as a direct pathway for delivering selected bacterial
proteins and active compounds to the host. In fact, vesicles released by gut microbiota
are emerging as key players in signaling processes in the intestinal mucosa. In the
present study, the dextran sodium sulfate (DSS)-induced colitis mouse model was used
to investigate the potential of EcN OMVs to ameliorate mucosal injury and inflammation
in the gut. The experimental protocol involved pre-treatment with OMVs for 10 days
before DSS intake, and a 5-day recovery period. Oral administration of purified EcN
OMVs (5 µg/day) significantly reduced DSS-induced weight loss and ameliorated clinical
symptoms and histological scores. OMVs treatment counteracted altered expression
of cytokines and markers of intestinal barrier function. This study shows for the first
time that EcN OMVs can mediate the anti-inflammatory and barrier protection effects
previously reported for this probiotic in experimental colitis. Remarkably, translation
of probiotics to human healthcare requires knowledge of the molecular mechanisms
involved in probiotic–host interactions. Thus, OMVs, as a non-replicative bacterial form,
could be explored as a new probiotic-derived therapeutic approach, with even lower
risk of adverse events than probiotic administration.
Keywords: probiotic, Escherichia coli Nissle 1917, outer membrane vesicles, DSS-experimental colitis, mouse
model, immune modulation
Abbreviations: Cox-2, cyclooxygenase 2; DAI, disease activity index; DSS, dextran sodium sulfate; EcN, Escherichia coli
Nissle 1917; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hBD-2, human β-defensin; IBD, inflammatory bowel
diseases; iNOS, inducible nitric oxide synthase; LB, Luria-Bertani broth; LPS, lipopolysaccharide; MIP-2, macrophage
inflammatory protein 2; MMPs, matrix metalloproteinases; NO, nitric oxide; OMVs, outer membrane vesicles; PAGE,
polyacrylamide gel electrophoresis; PBMCs, peripheral blood mononuclear cells; PBS, phosphate buffered saline; PRRs,
pattern-recognition receptors; SDS, sodium dodecyl sulfate; TEM, transmission electron microscopy; TFF-3, trefoil factor
3; TJ, tight junction; TLRs, toll-like receptors; TNF-α, tumor necrosis factor-α; Treg, regulatory T cells; UC, ulcerative colitis;
ZO-1, zonula occludens-1.
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INTRODUCTION
The term IBD mainly refers to UC and Crohn’s disease.
These are chronic inflammatory disorders of the intestinal tract
that may cause life-threatening complications and have an
increasing incidence worldwide. They are multifactorial diseases,
and although their etiology remains poorly understood, they
involve a dysregulated immune response against commensal gut
microbes in genetically susceptible individuals with impaired
intestinal epithelial integrity (Zhang and Li, 2014). Moreover,
several studies have reported that IBD patients have lower
microbiota diversity than healthy subjects, and an altered
intestinal microbiota balance, which is known as dysbiosis
(Ott et al., 2004; Sokol et al., 2008; Manichanh et al., 2012).
Conventional IBD therapies are complex, and not all patients
show complete beneficial effects when treated with any of the
drugs currently available to manage these intestinal conditions,
including salicylates, corticoids, immunosuppressants and
biological agents (Ko and Auyeung, 2014). Since dysbiosis is
common in IBD, various therapeutic approaches targeting the
modulation of the gut microbiota have been explored (Qiao
et al., 2016). In this context, many studies have evaluated the
therapeutic potential of certain bacteria, including commensal
and probiotic strains, to ameliorate IBD in clinical trials
(Fedorak, 2010; Wasilewski et al., 2015) or in animal models
of colitis (Ewaschuk et al., 2008; Garrido-Mesa et al., 2011;
Shen et al., 2012; Kang et al., 2013; Martín et al., 2015; Souza
et al., 2016). Overall, these studies have shown the ability of
these bacteria to exert beneficial effects on parameters related
with gut function, including improvement of gut permeability,
reduction of inflammatory cytokine production and/or release,
and amelioration of the histological alterations observed in these
inflammatory conditions. In some cases, these effects may be
mediated, at least in part, by bacterial secreted factors (Ewaschuk
et al., 2008; Martín et al., 2015) or by released membrane vesicles
(Shen et al., 2012; Kang et al., 2013).
The probiotic EcN positively affects gastrointestinal
homeostasis and microbiota balance. In fact, various clinical
trials have reported its therapeutic benefits in inducing and
maintaining remission of UC (Scaldaferri et al., 2016). EcN
shows similar efficacy to the aminosalicylate mesalazine
(Losurdo et al., 2015), which supports its use in the treatment
of human UC (Floch et al., 2011). Similarly, the intestinal
anti-inflammatory effects of this probiotic have been reported
in experimental models of colitis in mice and rats (Grabig et al.,
2006; Ukena et al., 2007; Arribas et al., 2009; Garrido-Mesa
et al., 2011; Souza et al., 2016). Several mechanisms have been
reported to be involved in the beneficial effects of this probiotic
in IBD, such as its ability to modulate the host immune response
toward an anti-inflammatory balance (Trebichavsky et al., 2010).
In addition, EcN reinforces the intestinal epithelial barrier by
strengthening TJs between intestinal epithelial cells (Ukena et al.,
2007; Zyrek et al., 2007; Hering et al., 2014) and increasing the
expression of antimicrobial factors such as microcins (Sassone-
Corsi et al., 2016) and β-defensin-2 (Schlee et al., 2007). It is
important to note that these effects were mainly established
when live probiotic suspensions were administered. There is
little reported information describing the bacterial factors
that could mediate these effects. In this context, membrane
vesicles released by commensal bacteria are currently receiving
great attention as key players in signaling processes in the
intestinal mucosa (Kaparakis-Liaskos and Ferrero, 2015; Olsen
and Amano, 2015). The release of bacterial vesicles provides
a mechanism for the delivery of microbial proteins and active
compounds directly to the host, thus avoiding direct intercellular
contact. Recently, it has been reported that OMVs released by
the probiotic EcN enter intestinal epithelial cells via clathrin-
mediated endocytosis, and thereby can trigger host immune and
defense responses (Cañas et al., 2016). In fact, in vitro and ex
vivo studies have shown that EcN OMVs induce the expression
of antimicrobial peptides and modulate the cytokine/chemokine
response of gut epithelial and immune cells (Fábrega et al.,
2016). In addition, in intestinal epithelial cell lines, these vesicles
promote upregulation of the TJ-proteins ZO-1 and claudin-14,
but down-regulation of claudin-2, thus reinforcing intestinal
barrier functions and reducing gut permeability (Alvarez et al.,
2016).
Probiotics are Generally Regarded As Safe (GRAS), yet some
concerns about the potential risk associated with their use should
be considered, especially in immunocompromised individuals
and neonates. In conditions of altered intestinal barrier, the
probiotic may cause invasive infections leading to sepsis (Ledoux
et al., 2006; Bleich et al., 2008; Gronbach et al., 2010). In
this context, the use of probiotic- derived bioactive factors,
such as OMVs, could potentially have healing benefits, while
avoiding the risks associated with the administration of live
bacteria.
Based on previous in vitro studies (Alvarez et al., 2016; Fábrega
et al., 2016) we hypothesized that EcN OMVs may contribute to
the immunomodulatory and barrier strengthening effects of EcN
in the gut. The aim of the present study was to evaluate the effects
of OMVs isolated from EcN in the dextran sodium sulfate (DSS)
model of mouse colitis, an experimental model that is widely used
in preclinical assays to study new potential treatments for human
IBD (Claes et al., 2011).
MATERIALS AND METHODS
EcN Culture and OMVs Preparation
The probiotic strain EcN (serotype O6:K5:H1) was provided by
Ardeypharm (GmbH, Herdecke, Germany). OMVs were isolated
from culture supernatants of EcN grown overnight at 37◦C in
Luria-Bertani broth (LB) as previously described (Aguilera et al.,
2014). Briefly, bacterial cells were pelleted by centrifugation at
10,000 × g for 20 min at 4◦C. The supernatant was filtered
through a 0.22 µm-pore-size filter (Millipore) to remove residual
bacteria, concentrated by centrifugation in a Centricon Plus-70
filter device (Millipore) followed by an additional filtration step.
OMVs were then recovered by centrifugation at 150,000 × g for
1 h at 4◦C, washed and resuspended in sterile PBS. Aliquots were
stored at−20◦C. The sterility of samples was assessed on LB-agar
plates. Protein concentration was measured using the method of
(Lowry et al., 1951).
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Negative Staining and Transmission
Electron Microscopy
Isolated OMVs were examined by transmission electron
microscopy (TEM) after negative staining as described previously
(Aguilera et al., 2014). A drop of OMV suspension was adsorbed
for 2 min on Formvar/carbon coated-grids that were previously
activated by UV light. Grids were washed with distilled water,
stained with 2% uranyl acetate for 1 min, air dried and examined
by TEM (Jeol, JEM 1010, Japan).
Dextran Sodium Sulfate (DSS) Model of
Mouse Colitis
All studies were carried out in accordance with the “Guide for
the care and the Use of Laboratory Animals” as promulgated
by the National Institute of Health. The protocol was approved
by the Ethics Committee of the University of Granada (Ref. No.
CEEA-2010-286). Male C57BL/6J mice (7- to 9-weeks-old;
approximately 20 g) were obtained from Janvier (St Berthevin
Cedex, France). Animals were randomly assigned to three groups:
non-colitic (n = 6), colitic (n = 9) and OMVs-treated (n = 9).
Mice were fed ad libitum during the entire experimental period
(20 days) on AIN-93G growth purified diet, and animal body
weight, as well as food and water intake, were evaluated daily. The
experimental design is shown in Figure 1. Every day throughout
the experimental period (20 days), the two reference groups
(non-colitic and colitic) received PBS solution (200 µl), and the
treated group received EcN OMVs (5 µg in 200 µl of PBS) by
means of an oesophageal catheter. Ten days after starting the
experiment, colitis was induced by adding DSS (36–50 kDa, MP
Biomedical, Scarborough, ON, United States) to the drinking
water at a final concentration of 3% (Mähler et al., 1998).
This treatment was applied to all groups for 5 days, except
for mice from the reference non-colitic group, which drank
tap water throughout the experiment. During this DSS-induced
colitis period, the OMVs-treated group was daily administered
with EcN OMVs (5 µg/mouse in 200 µl PBS). After colitis
damage, 200 µl of PBS were administered daily to all groups
except for the OMVs-treated model, which continued with
the OMVs treatment for five additional days. All mice were
sacrificed 20 days after beginning of the experiment. Animals
were previously anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg). After starting the DSS intake, animal body
weight, the presence of gross blood in the feces and stool
consistency were individually evaluated daily (by an observer
who was unaware of the treatment). Each parameter was
assigned a score according to the criteria proposed previously by
(Cooper et al., 1993) and used to calculate an average daily DAI
(Table 1).
Once mice were sacrificed, the colon was excised from
anus to caecum, emptied and washed with PBS before being
measured and weighed. Representative specimens (0.5 cm
length containing all wall layers) were taken from the distal
inflamed region and fixed in 4% buffered formaldehyde
for histological analysis. Other fragments were placed in
RNA later stabilization reagent (Qiagen GmbH, Hilden,
Germany) and stored at −80◦C until RNA extraction.
The remaining colonic tissue was subsequently sectioned in
different longitudinal fragments to be used for biochemical
determinations.
Colonic Organ Culture and ELISA Assays
Small fragments of colonic tissue were weighted, cut and
then cultured in DMEM (Gibco, Grand Island, NY, United
States) supplemented with 10% (v/v) of heat inactivated fetal
bovine serum, 1% penicillin/streptomycin, 1% amphotericin, 2%
glutamine and 0.45% glucose and incubated at 37◦C in a 5% CO2
atmosphere. After 24-h culture, the supernatants were collected,
centrifuged and stored at−80◦C until assay. IL-1β, IL-6 and IL-10
levels were measured using enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, United States)
according to the manufacturer’s instructions. The results were
expressed as pg/mg protein.
Histological Studies
The colonic samples that were fixed in formaldehyde were
paraffin-embedded, sectioned (5 µm) at different levels, and
stained with haematoxylin and eosin. Tissues were reviewed
in a blinded fashion and the histological damage was assessed
according to a previously validated intestinal histologic
inflammatory score (Camuesco et al., 2012). This score takes
into account the presence of ulceration, infiltration, oedema
and the condition of crypts. After evaluation of these features a
score ranging from 0 (healthy tissue) to 3 or 4 (severe damage),
depending on the item, was assigned to each one. For each
sample, the total score was calculated from the sum of each item’s
score.
Gene Expression Analysis in Colonic
Samples by RT-qPCR
Tissue was homogenized in 1 ml of QIAzol using a Precellys
24 homogenizer (Bertin Technologies, Montigny-Le bretonneux,
France). Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s protocol. Purity
and RNA concentration were measured by the absorbance ratio
at 260 and 280 in a Thermo Scientific Nano Drop TM 2000
Spectrophotometer. RNA integrity was verified by visualization
of 28S and 18S rRNAs after 1% agarose/formaldehyde gel
electrophoresis. RNA (2 µg) was reverse transcribed using oligo
(dT) primers (Promega, Southampton, United Kingdom). The
resulting cDNA (20 ng) was amplified on optical grade 48-
well plates in an EcoTM Real Time PCR System (Illumina,
San Diego, CA, United States), using the KAPA Sybr Fast
qPCR Master Mix (Kapa Biosystems, Inc., Wilmington, MA,
United States) and specific primers for each gene (Table 2).
The 2−11Ct method was used to normalize expression results.
The values of the housekeeping glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene were used to normalize the
values obtained for each of the genes under study. Relative
gene expression was calculated by means of the 11Ct formula
and expressed as fold-change compared with the non-colitic
control.
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FIGURE 1 | Experimental design to evaluate the potential of EcN OMVs to alleviate DSS-induced colitis in mice. The OMV-treated group daily received
intragastrically 200 µl of PBS containing 5 µg of EcN OMVs over the 20-day experimental period, whereas the colitic group received 200 µl of PBS. The non-colitic
control group was not challenged with DSS and received 200 µl of PBS over the entire experimental period.
SDS–PAGE and Western Blot Analysis
Protein concentration of colonic samples was measured using
a BCA Protein Assay Kit. The intestinal inducible isoform of
nitric oxide synthase (iNOS) was analyzed by Western blot.
Samples (50 µg protein) were mixed with SDS–PAGE sample
buffer, boiled for 5 min at 95◦C and electrophoresed on
6% SDS–PAGE gel. Proteins were transferred to a HyBond-P
polyvinylidene difluoride membrane using a Bio-Rad Mini
Transblot apparatus. The membrane was blocked in PBS-0.05%
Tween-20 and 5% skimmed milk (blocking solution) for
1 h at room temperature, and then incubated with specific
antibodies against iNOS (Transduction Laboratories, Becton
Dickinson Biosciences, Madrid, Spain), 1:2,000 dilution in
blocking solution, for 16 h at 4◦C, followed by incubation with
peroxidase-conjugated anti-rabbit IgG antibody (1:3,000) for 1 h.
The protein-antibody complex was visualized using the ECL
Plus Western blotting detection system (Amersham Pharmacia
Biotech). Control of protein loading and transfer was conducted
by detection of the β-actin levels.
Statistics
Statistical analysis was performed using SPSS version 20.0
software (SPSS, Inc.) and GraphPad Prism version 6.0 (GraphPad
Software Inc., La Jolla, CA, United States), and data were
expressed as mean ± SEM. Differences between more than two
TABLE 1 | Scoring index for disease activity.
Score Weight loss (%) Stool consistency Rectal bleeding
0 None Normal Normal
1 1–5
2 5–10 Loose stools
3 10–20
4 >20 Diarrhea Gross bleeding
Disease Activity Index was calculated by adding combined scores for weight loss,
stool consistency and rectal bleeding, and dividing the resulting global score by
three. Adapted from Cooper et al. (1993).
groups were assessed using one-way ANOVA followed by Tukey’s
test. Significant differences were established at P ≤ 0.05.
RESULTS
EcN OMVs Improve Clinical Signs and
Colonic Histology in DSS-Induced
Mouse Colitis
OMVs were isolated from cell-free culture supernatants and
evaluated by negative stain-TEM. Images showed spherical
vesicles ranging in size from approximately 20–60 nm in diameter
(Figure 2).
The in vivo protective effects of EcN OMVs were evaluated in
male C57BL/6J mice treated with 3% DSS following the protocol
outlined in Figure 1, which involves pre-treatment with OMVs
for 10 days before DSS intake, and a 5-day recovery period. The
administration of EcN OMVs for 10 days before DSS intake
did not result in significant modifications in body weight in
comparison with non-treated mice. Body weight increase was
around 15–17% in all groups. When DSS was orally administered
to mice, the intestinal inflammatory status was induced, and
characterized in the control colitic group (DSS control) by
marked body weight loss (Figure 3A) and diarrhea with bleeding
feces, which resulted in an increased DAI score in this group from
day 5 (Figure 3B). The administration of EcN OMVs to colitic
mice (DSS-OMVs) ameliorated body weight loss (Figure 3A) and
notably reduced the DAI score from day 6 after DSS intake in
comparison with the control colitic group. Statistically significant
differences were obtained on the last day of the study (Figure 3B).
Once mice had been sacrificed, macroscopic evaluation of colonic
segments confirmed the beneficial impact of EcN OMVs on the
inflammatory process. In fact, colon length is inversely associated
with the severity of DSS-induced colitis (Pandurangan et al.,
2015), and the colonic weight/length ratio is widely used as
an indicator of the colonic oedema that typically occurs in
experimental colitis (Hou et al., 2014). The colonic weight/length
ratio values were significantly higher in the colitic group than in
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TABLE 2 | Primer sequences used for quantitative RT-PCR.

















































the OMVs-treated group (Figure 3C), thus revealing that EcN
OMVs intake attenuated the colonic oedema associated with
DSS-induced intestinal inflammation in mice.
Microscopic evaluation of the colonic samples also evidenced
the intestinal anti-inflammatory effects of EcN OMVs on
DSS-induced colitis. Intestinal tissue from the control
colitic group revealed common characteristics that were
previously reported for this experimental model of colitis
(Algieri et al., 2014), including mucosal ulceration, with
loss of the normal crypt structure and intense goblet cell
depletion, together with inflammatory cell infiltration and
oedema (Figure 4A). Evaluation of colonic damage by the
scoring method described above yielded high histological
scores in colitic mice (DSS control group). In contrast, the
colitic group treated with EcN OMVs showed recovery
from the inflammatory process with an improvement in
mucosal barrier integrity, as evidenced by a smaller ulceration
surface and the presence of goblet cells replenished with
their mucin content. In addition, samples from mice treated
with OMVs showed lower inflammatory cell infiltration and
tissue oedema than samples from the control colitic group.
Consistently, microscopic evaluation of colonic damage in the
OMV-treated colitic mice resulted in significant improvement
in the histologic scores (P < 0.05 vs. control colitic group)
(Figure 4B).
Intestinal Anti-inflammatory Effects of
EcN OMVs Are Associated with an
Improvement in the Altered Immune
Response in DSS-Induced Mouse Colitis
It is well-known that DSS-induced colonic inflammation is
associated with an altered immune response (Xu et al., 2014).
Consistently, results from the RT-qPCR analysis performed
in the present study revealed that mice from the colitic
group showed significant higher mRNA expression of the
pro-inflammatory cytokines IL-1β, TNF-α, IL-6, MIP-2 and
INFγ than the non-colitic group. A trend of higher expression
of cytokines IL-12 and IL-17 was also observed in the colitic
group but the values did not reach statistical significance
when compared with non-colitic mice. The treatment of
colitic mice with EcN OMVs decreased the expression of
all pro-inflammatory cytokines assayed. The results were
statistically significant for IL-1β, TNF-α and IL-17 in comparison
with control colitic mice (Figure 5A). Moreover, the colonic
inflammatory process induced by DSS was associated with
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FIGURE 2 | Negative staining electron microscopy of isolated EcN OMVs.
Vesicles were isolated from 1-liter LB culture of EcN and resuspended in a
final volume of 0.2 ml PBS. A representative image of OMV samples (1:20
dilution) is shown. Scale bar: 200 nm.
lower expression of the anti-inflammatory cytokine IL-10, which
was significantly counteracted by administration of EcN OMVs
(Figure 5A).
The observed changes in colonic mRNA expression correlated
well with the protein levels, as evidenced from the quantitative
ELISA results of three representative cytokines (IL-10, IL-6 and
IL-1β) (Figure 5B). Levels of the pro-inflammatory cytokines
IL-6 and IL-1β were significantly lower in the colitic group
treated with EcN OMVs than in the corresponding control group
(DSS control). Administration of EcN OMVs counterbalanced
the DSS-mediated reduction in the colonic levels of the
anti-inflammatory cytokine IL-10, although these results did not
reach statistical significance, probably due to variability in the
data (Figure 5B).
The beneficial effects of EcN OMVs were also associated
with the recovery of a marker of intestinal barrier function, the
intestinal TFF-3, whose expression is downregulated in inflamed
colonic tissue after DSS administration to mice. It is interesting
to note that EcN OMVs restored the mRNA levels of TFF-3 to
values similar to those found in the non-colitic control group
(Figure 6). Treatment with EcN OMVs did not counteract
DSS-induced downregulation of ZO-1, but tended to increase
occludin mRNA levels in DSS-treated mice, although data did
not reach statistical significance (Figure 6). In the context of
tissue remodeling, we also measured the mRNA expression of two
relevant MMPs, MMP-9 and MMP-2, which have opposing roles.
MMP-9 promotes tissue injury in colitic mice, whereas MMP-
2 has a protective role and contributes to the maintenance of
gut barrier function (Garg et al., 2009). Accordingly, mice in the
colitic group showed greater expression of MMP-9 and lower
expression of MMP-2 than non-colitic mice. Both DSS-mediated
effects were countered by treatment with EcN OMVs, but only
the reduction in colonic MMP-9 mRNA levels was statistically
significant (Figure 6). Consequently, the effects exerted by EcN
OMVs on the altered expression of MMPs during colitis can
contribute to their ability to protect against tissue damage
induced by DSS.
In addition, RT-qPCR analysis was performed for the
inflammatory enzymes COX-2 and inducible iNOS, known to
be upregulated in DSS-induced colitis. Administration of EcN
OMVs to colitic mice significantly reduced the expression of both
enzymes, which were highly expressed in the colonic tissue of
untreated colitic mice (Figure 7A). Western blotting of iNOS
confirmed the compensatory effect mediated by EcN OMVs at
protein level (Figure 7B).
DISCUSSION
The etiology of IBD has not been completely elucidated to date.
However, it has been proposed that intestinal dysbiosis is crucial,
since it can promote an inappropriate immune response in
FIGURE 3 | EcN OMVs treatment improves clinical signs of DSS-induced colitis in mice. After the 10-day pre-treatment period, mice received 3% DSS in drinking
water for 5 days. Mice were sacrificed 5 days later. Mice from the OMVs-treated group (triangles; n = 9) were administered with EcN OMVs (5 µg/day) throughout the
experiment, whereas the two other experimental groups, colitic DSS control (squares; n = 9) and non-colitic control (circles; n = 6), received PBS instead. (A) Weight
evolution in animals over the DSS-treatment and the recovery period. Values are presented as percentage of the body weight at the beginning of DSS intake (day 0).
(B) DAI score of each experimental group from the beginning of the induction of colitis by DSS treatment (day 0) until sacrifice (day 10), calculated as described in
the Section “Materials and Methods.” (C) Colon weight/length ratio calculated following resection. Data are expressed as means ± SEM. Different letters indicate
significant differences between groups (P < 0.05).
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FIGURE 4 | EcN OMVs treatment promotes recovery of DSS-induced intestinal injury and inflammation in mice. On day 20, colons were excised and processed for
microscopic analysis. (A) Histological images of colonic tissue stained with haematoxylin and eosin showing the effect of EcN OMVs on DSS-induced colitis.
Representative images of each experimental group are shown: Control, DSS control and DSS OMVs. In Control, images show the normal appearance of the intact
mucosa containing the crypts with goblet cells plenty of their mucin content (arrows). In DSS control, images show changes in the mucosa with areas of ulceration
on the epithelial layer (asterisks), reduction of goblet cells with depletion of their mucin content (arrows) and intense inflammatory cell infiltrate (cross). In DSS OMVs,
an improvement of the colonic histology is observed, with reduced area of ulceration, mostly in process of recovery (asterisks), presence of goblet cells replenished
with their mucin content (arrow) and reduced inflammatory cell infiltrate (cross). (B) Histological scores calculated after microscopic analyses of longitudinal colon
sections as described in the Section “Materials and Methods.” Results are expressed as mean ± SEM. Control group (n = 6), DSS control group (n = 9), DSS OMVs
group (n = 9). Different letters indicate significant differences between groups (P < 0.05).
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FIGURE 5 | Effects of EcN OMVs treatment on colonic cytokine expression in DSS colitic mice. (A) Relative mRNA levels of the indicated cytokines measured by
RT-qPCR in colonic tissue. Data are presented as fold-change compared to the non-colitic control group (expression value set to 1). (B) IL-10, IL-1β and IL-6 protein
levels measured by ELISA in culture supernatants of colonic fragments from mice of each experimental group incubated for 24 h in complete DMEM medium as
described in the Section “Materials and Methods.” Data are expressed as mean ± SEM. Control group (n = 6), DSS control group (n = 9), DSS OMVs group (n = 9).
Different letters indicate significant differences between groups (P < 0.05).
genetically susceptible individuals, leading to the inflammatory
status that characterizes these intestinal conditions (Becker
et al., 2015). Accordingly, restoration of intestinal microbiota
composition through the administration of probiotics could
have beneficial effects against the inflammatory response, as
has been shown both in experimental models and in human
IBD (Claes et al., 2011; Bellaguarda and Chang, 2015). EcN
is one of the probiotics reported to have a beneficial effect in
IBD, and plays a prominent role in therapy for this group of
intestinal conditions in humans. In fact, the 2011 update of
the American Recommendations for Probiotic Use gave very
strong “A” recommendations for its use to maintain remission
in human UC (Floch et al., 2011). The therapeutic efficacy of
EcN has been more recently supported in a systematic review
and meta-analysis (Losurdo et al., 2015). Among the mechanisms
that might be involved in the beneficial effects exerted by EcN,
its immunomodulatory properties could play a key role. In the
gut, the probiotic can counteract altered cytokine production
by immune cells (Sturm et al., 2005; Guzy et al., 2008) and
restore damaged epithelium through the modulation of TJ and
zonula occludens proteins (Ukena et al., 2007; Zyrek et al.,
2007). Although direct interaction between the bacteria EcN
and the immune or epithelial cells could be responsible for the
observed effects, other mechanisms involving the production
and release of secreted bacterial factors cannot be ruled out.
Among these secreted factors, membrane vesicles play a key role
in bacteria–host communication, allowing the delivery of effector
molecules upon interaction and internalization into the host cells.
In fact, OMVs enclose many of the biological components that
can be found in the bacterium and, specifically, ligands of pattern
recognition receptors such as LPS (TLR-4 ligand), peptidoglycan
(NOD-1/NOD-2 ligand) or DNA (TLR-9 ligand), among others.
These receptors, which are expressed in epithelial and immune
cells, are key components of innate immunity as they sense gut
microbes and trigger appropriate immune responses. Therefore,
bacteria-released OMVs can mediate most of the effects of the
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FIGURE 6 | Effects of EcN OMVs treatment on colonic expression of markers of intestinal barrier function in DSS colitic mice. Relative mRNA levels of TFF-3,
MMP-9, MMP-2, ZO-1 and occludin were measured by RT-qPCR in colonic tissue. Data are presented as fold-change compared to the non-colitic control group.
Control group (n = 6), DSS control group (n = 9), DSS OMVs group (n = 9). Data are presented as mean ± SEM. Different letters indicate significant differences
between groups (P < 0.05).
bacterium. Remarkably, OMVs as non-replicative bacterial forms
further reduce the low risk of adverse events associated with the
administration of the probiotic (Bleich et al., 2008; Gronbach
et al., 2010; Olier et al., 2012).
Previous studies performed in human cell lines and human
colonic explants have shown the immunomodulatory and barrier
strengthening potential of EcN OMVs (Alvarez et al., 2016;
Fábrega et al., 2016). Since orally administered live EcN
suspensions ameliorate DSS-induced colitis in mice (Grabig et al.,
2006; Garrido-Mesa et al., 2011; Olier et al., 2012), we sought to
explore whether EcN OMVs could prevent colonic damage in the
same experimental model of intestinal inflammation. This is a
well-established animal model that resembles human UC, and it
has been validated for the translation of mouse data to humans
(Jiminez et al., 2015).
The present study demonstrates that oral administration
of OMVs isolated from EcN has intestinal anti-inflammatory
properties in the DSS experimental model of colitis, as previously
reported when a suspension of the viable probiotic was
administered (Garrido-Mesa et al., 2011). The beneficial effects
of EcN OMVs were already observed during the course of
the experiment. In fact, reduction in weight loss and DAI
evolution in mice treated with OMVs, compared to the control
colitic group, clearly evidenced amelioration of the impact of
the colitic process and improvement in the health status of
mice.
Likewise, OMVs administration to colitic mice significantly
reduced colonic damage. This was shown macroscopically by a
significant reduction in the colonic weight/length ratio, which
indicated amelioration of the tissue oedema that characterizes
this colonic inflammatory process, and microscopically with
recovery of the altered tissue histology associated with DSS
colitis. The OMV-mediated anti-inflammatory effect was clearly
associated with an improvement in the altered immune response
accompanying DSS-induced colonic damage, thus mimicking
the immunomodulatory properties described for this probiotic
both in vivo and in vitro (Kruis et al., 2004; Grabig et al.,
2006; Arribas et al., 2009; Garrido-Mesa et al., 2011; Scaldaferri
et al., 2016). It is known that the acute mucosal inflammation
induced by DSS results in activation of several cells involved
in the intestinal innate immune response, including epithelial
cells, macrophages and dendritic cells, leading to upregulated
expression and/or production of pro-inflammatory cytokines,
such as IL-1β, TNF-α and IL-6. This subsequently facilitates the
sustained inflammatory response associated with an imbalance
in Th1/Th17 and Treg cell responses, which results in increased
expression and/or production of other cytokines such as IFN-γ,
IL-12 (Th1) and IL-17 (Th17), together with a reduction in the
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FIGURE 7 | Effects of EcN OMVs treatment on colonic COX-2 and iNOS
expression. (A) Relative mRNA levels of COX-2 and iNOS measured by
RT-qPCR in colonic tissue. Data are presented as fold-change compared to
the non-colitic control group. Different letters indicate significant differences
between groups (P < 0.05). (B) Western blot analysis of iNOS levels in colonic
fragments collected from three mice (lines 1, 2, 3) of each group. Anti-β-actin
antibody was used as internal control. Representative images are shown.
anti-inflammatory cytokine IL-10 (Treg) (Neurath, 2014). Our
results show that administration of EcN OMVs ameliorates the
altered cytokine profile observed in colitic mice treated with DSS.
Different mechanisms could be involved in these
immunomodulatory properties. Of particular significance is
the ability to restore intestinal epithelial integrity. In this context,
it has been reported that the intestinal anti-inflammatory
properties of EcN are related to its ability to reinforce
TJs of intestinal epithelial cells, thus counteracting the
altered permeability status in the intestinal epithelium that
characterizes intestinal inflammation (Ukena et al., 2007).
Notably, impairment of the epithelial barrier function has
been proposed as one of the first events to occur in intestinal
inflammation. This facilitates the access of antigens from the
intestinal lumen and triggers the exacerbated immune response.
Consequently, rapid promotion of mucosal healing has been
considered crucial in the management of intestinal inflammation
(Dave and Loftus, 2012). Under conditions of intact epithelial
barrier EcN OMVs (100 µg/ml) upregulate expression of
claudin-14 and ZO-1 in T-84 and Caco-2 monolayers (Alvarez
et al., 2016). However, oral administration of EcN OMVs does
not prevent DSS-induced downregulation of ZO-1 mRNA.
Thus, the effects previously observed in in vitro models of intact
epithelial barrier are not appreciated in the in vivo model of
experimental colitis. This suggests that different regulatory
mechanisms could be activated by EcN OMVs in the presence
of highly expressed inflammatory mediators. Notably, ZO-1
is a target of post-translational modifications that regulate
the intracellular fate of this protein. Reinforcement of the
epithelial barrier can also be triggered by stimuli that promote
ZO-1 location at the cell boundaries, and hence its association
with TJ structures. In this context, it has been described that
TFF-3 promotes redistribution of ZO-1 from the cytoplasmic
compartment to the intercellular junctions in Caco-2 cell
monolayers, which results in an increased level of co-localisation
with occludin. These regulatory effects were not accompanied by
changes in ZO-1 or occludin protein levels (Buda et al., 2012).
Expression of TFF-3 is downregulated in intestinal inflammation
(Lozano-Pérez et al., 2014), as observed in the present study. In
connection with this, here we show that EcN OMVs increase
colonic expression of this bioactive peptide involved in epithelial
protection and repair (Podolsky et al., 2009), and preserve the
damaged colonic cytoarchitecture of the mucosa in colitic mice.
In addition to beneficial effects on epithelial integrity restoration,
increased expression of TFF-3 can help to ameliorate the altered
immune response exerted by EcN OMVs in experimental
colitis, since overexpression of this peptide has been reported to
abolish the IL-1β-induced upregulation of the pro-inflammatory
cytokines IL-6, IL-8 and TNFα (Lin et al., 2013). Another
plausible mechanism exploited by EcN OMVs to protect
intestinal barrier function in colitic mice is downregulation of
MMP-9 expression. Upregulation of this gelatinase contributes
to the pathogenesis of IBD by disrupting TJs between intestinal
epithelial cells, leading to increased intestinal permeability and
the subsequent pro-inflammatory effects (Nighot et al., 2015).
Moreover, treatment of colitic mice with EcN OMVs tends to
increase, or at least preserve, MMP-2 expression, thus protecting
against DSS-associated intestinal barrier loss (Garg et al., 2009).
Other markers of inflammation and tissue damage that
are over-expressed in DSS-induced colitis are COX-2 and
iNOS (Kolios et al., 2004). These enzymes are in fact defense
mechanisms against the injury, inflammation and infection that
occur in pathological conditions, and are highly expressed at
damaged sites. Increases in COX-2 levels are seen in chronic
intestinal inflammation, which is one of the risk factors for
colorectal cancer (Wang and DuBois, 2010). Expression of iNOS
is induced by certain pro-inflammatory cytokines such as TNF-α
or IFN-γ, as well as by bacterial products. Although increased
NO production through upregulation of iNOS is part of the
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intestinal antibacterial response, excess NO has been associated
with intestinal inflammation in IBD patients and attributed to the
immune dysregulation that occurs in these intestinal disorders
(Kolios et al., 2004). In fact, elevated iNOS expression has
been demonstrated in clinical IBD, caused mainly by infiltrating
macrophages in intestinal mucosa (Rachmilewitz et al., 1995;
Palatka et al., 2005). In addition, excessive NO production
mainly through iNOS has been correlated with tissue injury and
mucosal lesions observed in both human IBD and DSS-induced
colitic mice. Consequently, probiotics or natural compounds with
proven efficacy in attenuating colitis in DSS-treated mice reduce
iNOS expression (Camuesco et al., 2004; Garrido-Mesa et al.,
2015; Ren et al., 2015; Senol et al., 2015; Utrilla et al., 2015).
EcN is among these probiotics (Garrido-Mesa et al., 2011). Here
we show for the first time the ability of OMVs from a probiotic
strain, specifically EcN, to counteract DSS-induced expression of
both iNOS and COX-2. This correlates with reduced expression
of the pro-inflammatory cytokines TNF-α and IFN-γ, and lower
inflammatory cell infiltration in OMVs-treated mice.
At present, the molecules in EcN OMVs responsible for
the anti-inflammatory and/or barrier protective effects remain
unknown. Olier et al. (2012) reported that the genotoxic
polyketide colibactin is required for the in vivo anti-inflammatory
effects of EcN. Moreover, deficiency in colibactin biosynthesis
leads to exacerbation of colitis severity in DSS-treated mice.
These facts lead authors to considered colibactin as an
immunomodulin. Whether this bacterial effector is exported
and delivered into the host cells remains elusive. As EcN
OMVs exert anti-inflammatory effects in experimental colitis,
we may speculate that colibactin could be secreted through
OMVs, at least in part. However, the contribution of other
specific probiotic OMV-associated factors cannot be ruled out.
Regarding mediators of intestinal barrier protection, it has
been shown that the secreted protein TcpC contributes to the
in vitro strengthening ability of EcN when the epithelial barrier
is intact (Hering et al., 2014). However, the effect of TcpC is not
associated with OMVs (Alvarez et al., 2016). Thus, OMV-linked
factors other than TcpC should contribute to the modulation of
mucosal healing markers like TFF-3 and MMP-9, observed in this
experimental murine colitis model.
CONCLUSION
Recently acquired knowledge shows that microbiota plays an
important role in the pathogenesis of IBD; dysbiosis is a
common feature of these inflammatory conditions. Nowadays,
potential clinical applications of probiotics are being explored
to restore microbiota imbalances and take advantage of
their health-promoting capacities. However, the translation
of probiotics or microbiota-based drugs to human health-
care requires deep knowledge of the molecular mechanisms
involved in microbiota–host interactions (Jia et al., 2008;
Shanahan, 2011). In this regard, bacterial vesicles are key
players in signaling processes in the intestinal mucosa, as
they act as a secretion and delivery pathway for selected
bacterial proteins and active compounds directly to the host
cells. Among probiotics with promising results in IBD clinical
assays and experimental colitis models, EcN has beneficial
effects on the remission of UC. Our study proves that oral
administration of OMVs isolated from this probiotic has
intestinal anti-inflammatory effects in the DSS experimental
model of colitis, similarly as previously reported for the
administration of viable probiotic suspensions. Therefore, OMVs
could represent a safe probiotic-derived strategy targeting
intestinal inflammatory processes as they are free from bacteria
and can elicit the same effect on gastrointestinal health as the
probiotic itself.
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